Biogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke

Thursday, June 7, 2018 1 min read

Key Takeaway: Biogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke

Full Press Release Details

Biogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke.